Firstsource Solutions Q1 FY27 Earnings Call: Targets 14-15% EBIT Margin, Deal Pipeline Above USD1B (FSL)

Firstsource Solutions Ltd held its Q1 FY27 earnings call on August 06, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Financials & Profitability

• Rs.27.2B revenue — Q1 FY 2026-2027 revenue grew 22.9% YoY and 5.5% QoQ; in USD terms $288M, up 11.2% YoY; constant currency growth of 12.3% YoY and 2.2% QoQ.
• EBIT margin of 12.4% — expanded 110bps YoY and 20bps QoQ, marking the 7th consecutive quarter of margin expansion; EBITDA was Rs.3,367M, up 34.8% YoY.
• Adjusted PAT of Rs.2.2B — 8.2% of revenue, up 31.2% YoY and 8.3% sequentially; diluted EPS of Rs.2.36.
• Rs.717M exceptional charge — Q1 FY 2026-2027 included Rs.357M for a healthcare program termination, Rs.284M for an indemnified regulatory penalty, and Rs.76M for a fair value adjustment on a prior acquisition (net of tax: Rs.563M).
• Net debt of Rs.17.1B — as of 30 Jun 2026, versus Rs.16.3B at end-Mar 2026; normalized DSO of 67–69 days; free cash flow to PAT normalized at ~94%.
• Effective tax rate guided at 22–24% — for FY 2026-2027, due to moving to the new tax regime.

Deal Wins, Pipeline & Client Expansion

• 4 large deals in Q1 FY27 — 6th consecutive quarter with ≥4 large deals (ACV >$5M); ACV intake was the highest in the last four quarters; deal pipeline remains above USD1B.
• 12 new logos added — including 3 strategic logos; new logo wins exceeding $5M at outset are displacing incumbents, with 10–15 logos per quarter cited as proof of wider TAM.
• 145 clients >$1M revenue run rate — the $5M and $10M client cohorts each grew by 3 in Q1 FY 2026-2027; over the past two years, $5M+ clients are up 80% and $1M+ clients up 45%.
• Broad-based growth across geographies — North America grew 8% YoY CC; Europe grew 18% YoY; Australia doubled YoY.
• Revenue share of top 5 and top 10 clients declined — over the last 8 quarters, even as top 5 clients grew at industry rates, signaling broad-based additions and wallet deepening.
• H2 FY 2026-2027 expected to be stronger — revenue growth is expected to be stronger in the second half as recent wins ramp over the next ~3 months; total-year guidance reinforced.

Full-Stack Intelligence & Platform Adoption

• AI platforms live at scale for top lenders — deployed across 14 of the top 20 US mortgage lenders, 10 of the top 15 US health plans, and top 5 US and UK card issuers.
• Mortgage language model launched — a small language model addressing 200+ document ingestion scenarios; adoption is effective across nearly all mortgage clients.
• Kairos agentic OS driving deal wins — the new "full-stack intelligence operator" positioning and Kairos agentic OS are already contributing to the best deal wins in the past five quarters (including Q1 FY26-27).
• 5 new growth engines and 3 new capability frontiers — management stood up a US retail & CPG practice, marketing services, and security & resiliency services to pursue the next wave of demand.
• Non-linear commercial models require domain depth — management stated that strong domain orientation is a prerequisite for offering outcome-based models, and predicts divergence among players based on process-level domain knowledge.

Margin Bridge, Headcount & Hedging

• 12.4% EBIT margin in Q1 FY27 — ahead of the lower end of the FY 2026-2027 margin guidance range of 12.25%–12.75%; management maintains the 50–75bps annual margin expansion thesis.
• Headcount of 36,875 — net addition of 670 in Q1 FY 2026-2027; voluntary attrition of 27.5%.
• Segment margin fluctuations noted — BFS margins moved from 15% to 20% and Healthcare from 18% to low double digits, attributed to ramp-up costs in specific quarters, not systemic issues.
• Hedge book as of 30 Jun 2026 — GBP £61.6M at avg rate of 118–120; USD $119M at avg rate of Rs.92.7 over the next 12 months; 25–30% of the hedge portfolio consists of put options, allowing upside at current rates of 125–130 for GBP.
• Blended hedge rates disclosed — overall GBP portfolio approximately 123–124, USD approximately 94; hedging policy: 50–75% of committed year-one GBP book, ~25% of committed USD value.
• Rs.357M healthcare program termination charge — management described it as a conservative provision for vendor obligations; expects to recover amounts from the client; contractual recovery remains valid.

FY27 Outlook, Margin Target & Pipeline

• FY 2026-2027 guidance reiterated — constant currency revenue growth of 10%–13% and EBIT margin band of 12.25%–12.75%, held despite the healthcare contract wind-down.
• 14–15% EBIT margin target within 2–3 years — management "targets an EBIT margin of 14–15% within the next 2–3 years (by approximately FY30)," per the Q1 FY27 earnings call.
• Healthcare contract impact of ~1–1.5% — the wind-down of one B-pass healthcare payer engagement (client leadership change) impacted FY 2026-2027 revenue contribution; offset by portfolio strength, ramping large deals, and new logo momentum.
• Deal pipeline remains above USD1B — management expressed confidence in sustaining growth momentum across verticals in FY27, with gradual improvement expected in CMT and healthcare.
• Clients tied to exceptional items continue to grow — management expressed comfort with both the pipeline and wins from those clients, noting continued business expansion.
• One-time settlement with a different client — a commercial dispute in healthcare claims processing from a prior period has been remediated; the client continues to expand business with Firstsource.

Vertical Growth, Healthcare & BFS Trends

• BFS vertical grew 14% YoY CC — added 5 new logos in Q1 FY 2026-2027; segment margins ranged from 15% to 20% depending on ramp-up costs.
• Healthcare grew 11% YoY — but declined 2% sequentially; over a third of Q1 FY 2026-2027 deal wins were in healthcare, consistent with the vertical's ~33% revenue share.
• CMT grew 6% YoY and 9% QoQ — management expects gradual improvement in CMT and healthcare through the rest of FY 2026-2027.
• Diverse portfolio grew 27% YoY — reflecting strength in emerging verticals and the impact of new capability frontiers.
• Healthcare contract termination was isolated — attributed to a client-side leadership change, not a delivery issue; the client is a strategic logo with >US$5M annual revenue and continues to expand its relationship with Firstsource.
• Healthcare segment margins moved to low double digits — from 18% in prior periods, driven by ramp-up costs; management views this as temporary and not systemic.